The prognosis of breast cancer have improved as a result of long-term clinician's efforts.
Recently, 10 years recurrence free survival rate of breast cancer is very high.
However, the patients have to take the medication for a long time after surgery to prevent the metastasis and recurrence.
Till now, the short term treatment was known to affect the memory.
However, this news suggests that long term combined chemotherapy would decrease the memory ability for breast cancer after surgery.
CMF means the combined chemotherapy, which is included cyclophosphamide, methotrexate and 5-FU.
乳癌化学療法の認知機能への長期的な影響を調べたケースコホート研究で、20年以上前に術後CMF療法（シクロホスファミド、メトトレキサート、フルオロウラシル）を受けた乳癌女性では、癌の既往のない女性に比べて、認知機能がわずかだが統計的に有意に低下していることが明らかになった。化学療法は短期的に認知機能へ影響を及ぼすことが知られているが、長期的な影響を示したのは初めて。この結果はJournal of Clinical Oncology誌2月27日号に掲載された。
術後CMF療法による認知機能への影響は長期にわたり続く可能性：日経メディカル
However, the chemotherapy can actually improve the QOL of the patients.
So, we should be careful about our body and our memory during and after the treatment.
